20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Medtronic plc (NYSE:MDT) has secured European approval for its Hugo surgical robot.
- Hugo performed its first human procedure in June this year, a minimally invasive prostatectomy in Chile.
- It has since expanded to Latin America, with a series of initial gynecological surgeries completed in Panama.
- The robotic platform, made up of modular surgical arms on wheeled carts, has also checked off its first operation in the Asia-Pacific region through a prostatectomy in India.
- The Company's systems are linked to a global patient registry, which tracks outcomes and feeds that data back into the platform.
- The CE mark covers urologic and gynecologic procedures, such as hysterectomies and the removal of uterine fibroids.
- The Hugo system is designed to provide a lower barrier to entry for hospitals looking to expand their reach in robotic surgery.
- Related: Medtronic Expands Recall of MiniMed 600 Series Insulin Pumps.
- Price Action: MDT shares are down 0.40% at $124.77 during the market session on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!